529 results about "Uronic acid" patented technology

A composition comprising an amphoteric or pseudo-amphoteric agent and a polyhydroxy alpha hydroxyacid existing as a free acid, lactone, or salt, and isomeric or non-isomeric forms thereof is provided. The amphoteric or pseudo-amphoteric agent can be selected from amino acids, dipeptides, aminoaldonic acid, aminouronic acid, lauryl aminoproplyglycine, aminoaldaric acid, neuraminic acid desulfated heparin, deacetylated hyaluronic acid, hyalobiuronic acid, chondrosine, deacetylated chondroitin, creatine, creatinine, hydroxyproline, homocysteine, homocystine, homoserine, ornithine, citrulline, phosphatidylserine, and sphingomyelin. The composition may contain other additives, including cosmetic or pharmaceutical agents for topical treatment of dermatological disorders.

The present invention provides an alginate oligosaccharide and its derivatives with the degree of polymerization ranging from 2 to 22. The alginate oligosaccharide is composed of β-D-mannuronic acid linked by 1,4 glycosidic bonds. The derivatives with the reduced terminal in position 1 of carboxyl radical can be prepared by oxidative degradation. The present invention also provides a process for preparing the alginate oligosaccharide and its derivatives, which includes the procedures that an alginate solution is reacted for 2 to 6 h in an autoclave at pH 2-6 and the temperature of 100-120° C., and pH is adjusted to 7 after the reaction is stopped, after which the resultant oligosaccharide is oxidized in the presence of an oxidant to obtain an oxidative degradation product. The alginate oligosaccharide and its derivatives of the invention can be used in the manufacture of a medicament for the prophylaxis and treatment of AD and diabetes.

The present invention provides edible compositions comprising a source of non-solubilised divalent metal ions and from 0.1 to 6% wt of an alginate having an L-guluronic acid content of at least 60% of the total uronic acid units in the alginate. The compositions of the invention have good satiety effects and are beneficial for use in weight control plans. The edible compositions may be a food compositions intended for use in a weight loss or weight control plan such as a meal replacer food product.

Disclosed are compositions and methods for treating skin comprising a chemically compatible combination of skin active ingredients comprising palmitoyl tetrapeptide-7, methylsilanol mannuronate, and Lactobacillus ferment, a chemically compatible combination of skin active ingredients comprising plant extracts from Punica granatum, Castanea sativa, Gossypium hirsutum, and Euterpe oleracea, and a dermatologically acceptable vehicle. The compositions can be substantive in that they can remain on a person's skin during sleep.

Modified polysaccharide compositions and their use for treating subjects with cancer, preventing cancer in high-risk subjects and inhibiting metastasis in a subject are described. The modified polysaccharide includes a saccharide backbone being less than 5% esterified and containing repeating units, wherein each repeating unit has a plurality of uronic acid molecules, each repeating unit having at least one neutral monosaccharide attached thereto, at least one side chain of saccharides attached to the backbone further comprising a plurality of neutral saccharides or saccharide derivatives; and having an average molecule weight in the range of 15 to 60 kD.

The present invention provides a new class of compounds presenting a high compatibility with tissues and organic fluids. Such new compounds are polysaccharides essentially formed of units of uronic acid and / or hexosamine, containing nitro groups —ONO2 covalently bonded to the saccharide structure. Preferably, the polysaccharides according to the invention are prevalently formed of disaccharide repeating units formed of uronic acid and hexosamine. These compounds, in psychological conditions, selectively release NO, allowing a reduction in the amount of NO needed to achieve a determined therapeutical effect. This result has been achieved by functionalizing polysaccharides essentially formed of units of uronic acid and / or hexosamine, with subsituents containing a ONO2 ? group.

Provided are methods of producing 2,5-furandicarboxylic acid (FDCA) from renewable sources such as seaweed, alginate, oligoalginate, pectin, oligopectin, polygalacturonate, galacturonate, and / or oligogalacturonate. The sugars in the renewable sources can be converted into one or more intermediates such as 4-deoxy-L-erythro-5-hexoseulose uronate (DEHU), 4-deoxy-L-threo-5-hexosulose uronate (DTHU), 5-hydroxymethyl furfural (HMF), 2,5-dihydroxymethyl furan (DHMF), and 5-formyl-2-furancarboxylic acid (FFA), which can be converted into FDCA by dehydration and cyclization to produce 5-formyl-2-furancarboxylic acid (FFA), followed by oxidation to produce FDCA. DEHU or DTHU may also be converted into FDCA by oxidation to produce 2,3-dihydroxy-5-oxohexanedioic acid (DOHA), which then undergoes dehydration and cyclization to produce FDCA.

The invention provides sulfated heparin oligosaccharide as well as a preparation method and application thereof. The sulfated heparin oligosaccharide is characterized in that a non-reducing end of a sulfated heparin oligosaccharide molecule contains an unsaturated double bond produced through enzymolysis of heparinase as well as uronic acid derivatives and glycosylamine derivatives; the sulfated heparin oligosaccharide has a structure represented by a formula I, wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, Ra, Rb, Rc and Rd are independently SO3<-> or H; Rx', Ry' and Rz' are independently COCH3 or SO3<->, and n is 1-3. The sulfated heparin oligosaccharide with controllable sulfating degree prepared by virtue of the preparation method has very high activity for inhibiting heparanase in vitro, the activity of the sulfated heparin oligosaccharide for inhibiting cell adhesion and migration is 4-5 times higher than that of heparin, and the activity for inhibiting tumor metastasis in mice is 2-3 times higher than that of the heparin; the sulfated heparin oligosaccharide has relatively good tumor metastasis resistance and relatively high specificity.

The invention relates to a novel preparation method for agranular crosslinking sodium hyaluronate. Crosslinking reaction is performed in the low-concentration linear molecule state, and accordingly excess exposure of enzymatic-hydrolysis sites caused by crushing or extrusion of mechanical external forces of crosslinking sodium hyaluronate in traditional processes can be avoided. Redundant crosslinker can be eliminated effectively by white-powdered crosslinking sodium hyaluronate particles obtained by physical precipitation by using organic solvent, and accordingly accurate distribution of different concentrations of products can be guaranteed. The crosslinking sodium hyaluronate has the characteristics of high-temperature resistance, enzymatic-hydrolysis resistance and agranulation, and excellent injectability can be improved evidently. Kinetic viscosity of the agranular crosslinking sodium hyaluronate is reduced by 3-10% after sterilizing at 121 DEG C for 30 minutes, enzymatic hydrolysis is performed to 1000 U of sodium hyaluronate for 48 hours, and releasing amount of uronic acid is smaller than 40%.

The invention relates to an oligosaccharide metallic compound. The compound is characterized in that sugar residues of the compound consist of alpha-1, 4-L-guluronic acid; the weight average molecular weight of the compound is less than or equal to 12kD; and a molecular general formula of the compound is (C6H7O6)nCrm, wherein n is equal to 1 to 54, m is equal to 1 to 27 and the mass percentage of trivalent chromium is 0.1 to 12 percent. The preparation of the compound comprises the following steps: slowly adding chromic salt and dilute alkaline aqueous solutions in oligoguluronic acid aqueous solution under the conditions that pH is equal to 5 to 10 and temperature is between 40 and 80 DEG C; after stopping adding dilute alkaline and chromic salt aqueous solutions, carrying out heat-insulation reaction for 1 to 3h; carrying out filtration and precipitating the filtrate by ethanol with the volume 3 to 5 times that of the filtrate; carrying out static, precipitation and centrifugation; and collecting and washing the precipitate by using anhydrous ethanol to obtain the compound after drying. The oligosaccharide metallic compound has the advantages that because the raw materials are derived from marine natural products, the compound has abundant resources, easy industrialization, high safety, unique structure and ideal oral absorption and particularly integrates the advantages of marine oligosaccharide and trivalent chromium; and the compound not only has the functions of preventing insulin resistance and adjusting sugar and fat metabolism disturbance, but also has broad market and application prospects particularly in the prevention and treatment of diabetes II.

The invention discloses a quantitative detection method of polysaccharide containing uronic acid. The method comprises the following steps: preparing a standard polysaccharide solution and a sample solution to be tested; hydrolyzing polysaccharide in the standard solution and the sample solution to be tested so as to obtain hydrolyzed residue; derivatizing the residue with 1-phenyl-3-methyl-5-pyrazolone to prepare a sugar derivative; carrying out chromatographic analysis on the sugar derivative by the utilization of a high performance liquid chromatograph and a triple quadrupole linear ion trap mass spectrometer; determining which kind of polysaccharide containing uronic acid the sample to be tested is according to the chromatogram; and preparing a standard curve of chromatographic peak area and polysaccharide concentration according to the chromatogram of the standard polysaccharide disaccharide derivative obtained by high performance liquid chromatography-mass spectrum, and calculating content of polysaccharide containing uronic acid in the sample to be tested by the utilization of peak area of the sample to be tested. According to the method provided by the invention, quantitative detection of polysaccharides can be accurately carried out, and effective means is provided for quality control of products such as medicines, health product and the like of the polysaccharides.

The invention discloses a method for synchronously determining monosaccharide, uronic acid and saccharic acid in a wood fiber material reaction system. The method comprises the steps as follows: pretreating the wood fiber material reaction system to obtain a solution to be determined; determining standard samples of monosaccharide, uronic acid and saccharic acid by adopting an integrated pulse amperometric detection method and a chromatographic peak integration method and utilizing a high-performance liquid ion exchange chromatograph, thus obtaining a standard equation; determining the solution to be determined by utilizing the high-performance liquid ion exchange chromatograph and calculating the content of each component by utilizing the standard equation; and separating and quantifyingxylose and mannose in the solution to be determined by utilizing a high-performance liquid chromatography, and then amending the result of the high-performance liquid ion exchange chromatography. Themethod for synchronously, correctly and quantitatively determining the monosaccharide, the uronic acid and the saccharic acid is established for the first time, the separation degrees and the detection efficiencies of eight types of materials are improved greatly and the synchronous, correct and quantitative determination on nine types of materials in the wood fiber material reaction system can be realized under the combination of the high-performance liquid ion exchange chromatography; and the method has significance to matter changing, and component analysis and determination on products and intermediate products in bio-refinery process of the wood fiber material.

Glicosaminoglycans derived from K5 polysaccharide having high antithrombin activity and useful for the control of coagulation and as antithrombotic agents are obtained starting from an optionally purified K5 polysaccharide by a process comprising the steps of N-deacetylation / N-sulphation, C5 epimerisation of at least 40% of the glucuronic acid moiety, O-oversulphation, selective O-desuphation, 6-O-sulphation, N-sulphation, and optional depolymeration, and in which the selective O-desulphation step is carried out by treatment of the oversulphated product with a mixture dimethyl sulfoxide / methanol at a temperature of 50-70C for 135-165 minutes. New, particularly interesting antithrombin compounds are obtained by thus controlling the reaction time in the selective O-desulphation step and submitting the product obtained at the end of the final N-sulphation step to depolymeration.